

# Global IUCD Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

<https://marketpublishers.com/r/G061308FDE6EN.html>

Date: September 2017

Pages: 171

Price: US\$ 4,200.00 (Single User License)

ID: G061308FDE6EN

## Abstracts

In this region, global intra-uterine contraceptive devices market is projected to reach USD 4,851.2 million by 2024 from USD 3,684.1 million in 2016, at a CAGR of 3.5% in the forecast period 2017 to 2024.

Based on geography, the global intra-uterine contraceptive devices (IUCD) market is segmented into 5 geographical regions, such as,

North America,  
South America,  
Europe,  
APAC,  
MEA,  
Rest Of the World

Global intra-uterine contraceptive devices (IUCD) market competition by top players including -

Bayer AG dominated the IUCD market accounting largest market share followed by Teva Pharmaceuticals Industries Ltd., and Mona Lisa N.V. along with others such as include

DKT International,  
Egemen International,  
Melbea AG,  
Ocon Medical Ltd.,  
Pregna International Limited,

Medical Engineering Corporation SA  
SMB Corporation and Meril Life Sciences Pvt. Ltd.,  
Medu Scientific Ltd, China RH Contraceptives Co., Ltd,  
Sanghai Jolly Medical Education Co., Ltd,  
Bernstein Leibhard LLP,  
Zhejiang Daji Medical Instruments, Ltd.,  
Nimble International,  
AME Line, Technico,  
Cepeo,  
Contraceptivos,  
Injeflex Ind And Com Ltda,  
Bersil,  
Amed.

The global intra-uterine contraceptive devices market is segmented on the basis of product type, end user, and geography.

The global intra-uterine contraceptive devices market is segmented into 2 product types, namely copper IUCD and hormonal IUCD.

On the basis of end users the market is segmented into hospitals, gynaecology clinics, and community healthcare. In 2017, the hospital segment is expected to dominate the market and is expected to continue this trend till 2024.

## Contents

### **1. INTRODUCTION**

- 1.1. OVERVIEW OF GLOBAL INJECTABLE DRUG DELIVERY MARKET
- 1.2. CURRENCY AND PRICING
- 1.3. LIMITATION
- 1.4. MARKETS COVERED

### **2. MARKET SEGMENTATION**

- 2.1. MARKETS COVERED
- 2.2. GEOGRAPHIC SCOPE
- 2.3. YEARS CONSIDERED FOR THE STUDY
- 2.4. CURRENCY AND PRICING
- 2.5. RESEARCH METHODOLOGY
- 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.7. SECONDARY SOURCES
- 2.8. ASSUMPTIONS

### **3. MARKET OVERVIEW**

- 3.1. DRIVERS
  - 3.1.1. RISING CASES OF CHRONIC DISEASES
  - 3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
  - 3.1.3. GROWTH OF BIOLOGICS MARKET
  - 3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
- 3.2. RESTRAINTS
  - 3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
  - 3.2.2. HIGH COST OF DEVELOPMENT
  - 3.2.3. STRICT REGULATORY FRAMEWORK
- 3.3. OPPORTUNITY
  - 3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
    - 3.3.1.1. GENERICS
    - 3.3.1.2. BIOSIMILARS
  - 3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
  - 3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS
- 3.4. CHALLENGES

- 3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
- 3.4.2. PRODUCT RECALL
- 3.4.3. STABILITY OF PRODUCTS
- 3.4.4. STERILITY OF INJECTIONS

## **4. EXECUTIVE SUMMARY**

## **5. PREMIUM INSIGHTS**

## **6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY**

- 6.1. OVERVIEW
- 6.2. U.S. FDA APPROVAL
- 6.3. CE MARKING (EUROPEAN CONFORMITY)
- 6.4. EM (EUROPEAN MEDICINE AGENCY)

## **7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE**

- 7.1. OVERVIEW
- 7.2. INJECTable DRUG DELIVERY DEVICES
  - 7.2.1. CONVENTIONAL INJECTION DEVICES
  - 7.2.2. SELF INJECTION DEVICES
    - 7.2.2.1. NEEDLE FREE INJECTORS (NFI)
    - 7.2.2.2. AUTO INJECTORS
    - 7.2.2.3. PEN INJECTORS
    - 7.2.2.4. WEARABLE INJECTORS
- 7.3. INJECTable DRUG DELIVERY FORMULATION
  - 7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
    - 7.3.1.1. SOLUTIONS
    - 7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
    - 7.3.1.3. SUSPENSIONS
    - 7.3.1.4. EMULSIONS
  - 7.3.2. NOVEL DRUG DELIVERY FORMULATIONS
    - 7.3.2.1. COLLOIDAL DISPERSIONS
    - 7.3.2.2. MICROPARTICLES
    - 7.3.2.3. LONG ACTING INJECTION FORMULATION

## **8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION**

## 8.1. OVERVIEW

## 8.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

### 8.3. HORMONAL DISORDERS

#### 8.3.1. INJECTABLE DRUGS FOR DIABETES

#### 8.3.2. INJECTABLE DRUGS FOR ANEMIA

#### 8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE

#### 8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY

#### 8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS

#### 8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)

### 8.4. ONCOLOGY

### 8.5. AUTOIMMUNE DISEASES

#### 8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS

#### 8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS

#### 8.5.3. INJECTABLE DRUGS FOR CROHN'S DISEASES

#### 8.5.4. INJECTABLE DRUGS FOR PSORIASIS

#### 8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES

### 8.6. ORPHAN DISEASE

### 8.7. OTHER APPLICATIONS

#### 8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT

#### 8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT

#### 8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS

#### 8.7.4. INJECTABLE DRUGS FOR HEPATITIS C

#### 8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA

## 9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

### 9.1. OVERVIEW

### 9.2. CURATIVE CARE

### 9.3. IMMUNIZATIONS

### 9.4. OTHER USAGE PATTERN

## 10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

### 10.1. OVERVIEW

### 10.2. SKIN

### 10.3. CIRCULATORY/ MUSKOSKELETAL

### 10.4. ORGANS

### 10.5. CENTRAL NERVOUS SYSTEM

## **11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER**

- 11.1. OVERVIEW
- 11.2. HOSPITALS AND CLINICS
- 11.3. HOME HEALTHCARE SETTINGS
- 11.4. RESEARCH LABORATORIES
- 11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
- 11.6. OTHER END USERS

## **12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL**

- 12.1. OVERVIEW
  - 12.1.1. HOSPITAL PHARMACY
  - 12.1.2. PHARMACY STORES
  - 12.1.3. DIRECT TENDER
  - 12.1.4. ONLINE PHARMACY

## **13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY**

- 13.1. OVERVIEW
- 13.2. NORTH AMERICA INJECTable DRUG DELIVERY MARKET
  - 13.2.1. U.S. INJECTable DRUG DELIVERY MARKET
  - 13.2.2. CANADA INJECTable DRUG DELIVERY MARKET
  - 13.2.3. MEXICO INJECTable DRUG DELIVERY MARKET
- 13.3. EUROPE INJECTable DRUG DELIVERY MARKET
  - 13.3.1. GERMANY INJECTable DRUG DELIVERY MARKET
  - 13.3.2. FRANCE INJECTable DRUG DELIVERY MARKET
  - 13.3.3. UK INJECTable DRUG DELIVERY MARKET
  - 13.3.4. ITALY INJECTable DRUG DELIVERY MARKET
  - 13.3.5. SWITZERLAND INJECTable DRUG DELIVERY MARKET
  - 13.3.6. SPAIN INJECTable DRUG DELIVERY MARKET
  - 13.3.7. NETHERLAND INJECTable DRUG DELIVERY MARKET
  - 13.3.8. RUSSIA INJECTable DRUG DELIVERY MARKET
  - 13.3.9. TURKEY INJECTable DRUG DELIVERY MARKET
  - 13.3.10. BELGIUM INJECTable DRUG DELIVERY MARKET
  - 13.3.11. REST OF EUROPE INJECTable DRUG DELIVERY MARKET
- 13.4. APAC INJECTable DRUG DELIVERY MARKET

- 13.4.1. JAPAN INJECTable DRUG DELIVERY MARKET
- 13.4.2. CHINA INJECTable DRUG DELIVERY MARKET
- 13.4.3. SOUTH KOREA INJECTable DRUG DELIVERY MARKET
- 13.4.4. INDIA INJECTable DRUG DELIVERY MARKET
- 13.4.5. AUSTRALIA INJECTable DRUG DELIVERY MARKET
- 13.4.6. SINGAPORE INJECTable DRUG DELIVERY MARKET
- 13.4.7. THAILAND INJECTable DRUG DELIVERY MARKET
- 13.4.8. MALAYSIA INJECTable DRUG DELIVERY MARKET
- 13.4.9. INDONESIA INJECTable DRUG DELIVERY MARKET
- 13.4.10. PHILIPPINES INJECTable DRUG DELIVERY MARKET
- 13.4.11. REST OF APAC INJECTable DRUG DELIVERY MARKET
- 13.5. SOUTH AMERICA INJECTable DRUG DELIVERY MARKET
  - 13.5.1. BRAZIL INJECTable DRUG DELIVERY MARKET
  - 13.5.2. REST OF SOUTH AMERICA INJECTable DRUG DELIVERY MARKET
- 13.6. MEA INJECTable DRUG DELIVERY MARKET
  - 13.6.1. SOUTH AFRICA INJECTable DRUG DELIVERY MARKET
  - 13.6.2. REST OF MEA INJECTable DRUG DELIVERY MARKET

## **14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE**

- 14.1. COMPANY SHARE ANALYSIS: GLOBAL

## **15. COMPANY PROFILES**

- 15.1. BECTON, DICKINSON AND COMPANY
  - 15.1.1. COMPANY OVERVIEW
    - 15.1.1.1. DRIVERS EXPLAINED
    - 15.1.1.2. WEAKNESSES EXPLAINED
    - 15.1.1.3. OPPURTUNITIES EXPLAINED
    - 15.1.1.4. THREATS EXPLAINED
  - 15.1.2. PRODUCT PORTFOLIO
  - 15.1.3. RECENT DEVELOPMENTS
- 15.2. PFIZER
  - 15.2.1. COMPANY OVERVIEW
    - 15.2.1.1. DRIVERS EXPLAINED
    - 15.2.1.2. WEAKNESSES EXPLAINED
    - 15.2.1.3. OPPURTUNITIES EXPLAINED
    - 15.2.1.4. THREATS EXPLAINED
  - 15.2.2. PRODUCT PORTFOLIO

- 15.2.3. RECENT DEVELOPMENTS
- 15.3. BAXTER INTERNATIONAL
  - 15.3.1. COMPANY OVERVIEW
    - 15.3.1.1. DRIVERS EXPLAINED
    - 15.3.1.2. WEAKNESSES EXPLAINED
    - 15.3.1.3. OPPURTUNITIES EXPLAINED
    - 15.3.1.4. THREATS EXPLAINED
  - 15.3.2. PRODUCT PORTFOLIO
  - 15.3.3. RECENT DEVELOPMENTS
- 15.4. GERRESHEIMER AG
  - 15.4.1. COMPANY OVERVIEW
  - 15.4.2. PRODUCT PORTFOLIO
  - 15.4.3. RECENT DEVELOPMENTS
- 15.5. SCHOTT AG INC.
  - 15.5.1. COMPANY OVERVIEW
  - 15.5.2. PRODUCT PORTFOLIO
  - 15.5.3. RECENT DEVELOPMENTS
- 15.6. ALKERMES INC.
  - 15.6.1. COMPANY OVERVIEW
  - 15.6.2. PRODUCT PORTFOLIO
  - 15.6.3. RECENT DEVELOPMENTS
- 15.7. ANTARES PHARMA
  - 15.7.1. COMPANY OVERVIEW
  - 15.7.2. PRODUCT PORTFOLIO
  - 15.7.3. RECENT DEVELOPMENTS
- 15.8. BESPAC (SUBSIDIARY OF CONSORT MEDICAL COMPANY)
  - 15.8.1. COMPANY OVERVIEW
  - 15.8.2. PRODUCT PORTFOLIO
  - 15.8.3. RECENT DEVELOPMENTS
- 15.9. ELCAM MEDICAL
  - 15.9.1. COMPANY OVERVIEW
  - 15.9.2. PRODUCT PORTFOLIO
  - 15.9.3. RECENT DEVELOPMENTS
- 15.10. ELI LILLY AND COMPANY
  - 15.10.1. COMPANY OVERVIEW
    - 15.10.1.1. DRIVERS EXPLAINED
    - 15.10.1.2. WEAKNESSES EXPLAINED
    - 15.10.1.3. OPPURTUNITIES EXPLAINED
    - 15.10.1.4. THREATS EXPLAINED



- 15.10.2. PRODUCT PORTFOLIO
- 15.10.3. RECENT DEVELOPMENTS
- 15.11. HASELMEIER
  - 15.11.1. COMPANY OVERVIEW
  - 15.11.2. PRODUCT PORTFOLIO
  - 15.11.3. RECENT DEVELOPMENTS
- 15.12. MYLAN N.V.
  - 15.12.1. COMPANY OVERVIEW
  - 15.12.2. PRODUCT PORTFOLIO
  - 15.12.3. RECENT DEVELOPMENTS
- 15.13. NOVO NORDISK
  - 15.13.1. COMPANY OVERVIEW
  - 15.13.2. PRODUCT PORTFOLIO
  - 15.13.3. RECENT DEVELOPMENTS
- 15.14. OWEN MUMFORD LTD
  - 15.14.1. COMPANY OVERVIEW
  - 15.14.2. PRODUCT PORTFOLIO
  - 15.14.3. RECENT DEVELOPMENTS
- 15.15. SANDOZ INTERNATIONAL GMBH
  - 15.15.1. COMPANY OVERVIEW
  - 15.15.2. PRODUCT PORTFOLIO
  - 15.15.3. RECENT DEVELOPMENTS
- 15.16. SANOFI
  - 15.16.1. COMPANY OVERVIEW
  - 15.16.2. PRODUCT PORTFOLIO
  - 15.16.3. RECENT DEVELOPMENTS
- 15.17. TERUMO CORPORATION
  - 15.17.1. COMPANY OVERVIEW
  - 15.17.2. PRODUCT PORTFOLIO
  - 15.17.3. RECENT DEVELOPMENTS
- 15.18. TEVA PHARMACEUTICAL
  - 15.18.1. COMPANY OVERVIEW
    - 15.18.1.1. DRIVERS EXPLAINED
    - 15.18.1.2. WEAKNESSES EXPLAINED
    - 15.18.1.3. OPPURTUNITIES EXPLAINED
    - 15.18.1.4. THREATS EXPLAINED
  - 15.18.2. PRODUCT PORTFOLIO
  - 15.18.3. RECENT DEVELOPMENTS
- 15.19. WEST PHARMACEUTICAL SERVICES, INC

- 15.19.1. COMPANY OVERVIEW
- 15.19.2. PRODUCT PORTFOLIO
- 15.19.3. RECENT DEVELOPMENTS
- 15.20. YPSOMED HOLDING AG
  - 15.20.1. COMPANY OVERVIEW
  - 15.20.2. PRODUCT PORTFOLIO
  - 15.20.3. RECENT DEVELOPMENTS

## 16. RELATED REPORTS

### LIST OF TABLE:

- Table 1 EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS ( )(2013- 2017)
- Table 2 NUMBER OF NEEDLESTICK INJURIES
- Table 3 LIST OF PRODUCT RECALL DRUGS
- Table 4 LIST OF DIFFERENT TYPES OF APPROVAL FOR DIFFERENT COUNTRIES
- Table 5 GLOBAL INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
- Table 6 GLOBAL INJECTable DRUG DELIVERY DEVICES MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
- Table 7 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY MATERIAL, 2015 – 2024 (USD MILLION)
- Table 8 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
- Table 9 GLOBAL CONVENTIONAL DRUG DELIVERY MARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
- Table 10 GLOBAL SELF INJECTION DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
- Table 11 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
- Table 12 GLOBAL NEEDLE FREE INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
- Table 13 GLOBAL NEEDLE FREE INJECTORS DEVICE ARKET, BY USABILITY, 2015 – 2024 (USD MILLION)
- Table 14 GLOBAL AUTO INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)
- Table 15 GLOBAL AUTO INJECTOR DEVICES MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)
- Table 16 GLOBAL AUTO INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024

(USD MILLION)

Table 17 GLOBAL AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024

(USD MILLION)

Table 18 GLOBAL PEN INJECTOR DEVICES MARKET, BY PRODUCT, 2015 – 2024

(USD MILLION)

Table 19 GLOBAL PEN INJECTOR DEVICES MARKET, BY DESIGN, 2015 – 2024

(USD MILLION)

Table 20 GLOBAL PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024

(USD MILLION)

Table 21 GLOBAL INJECTable DRUG DELIVERY FORMULATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

Table 22 LIST OF SOME OF THE LYOPHILIZED FORMULATIONS

Table 23 LIST OF SOME OF THE EMULSIONS

Table 24 GLOBAL CONVENTIONAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

Table 25 GLOBAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

Table 26 GLOBAL COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

Table 27 LIST OF SOME OF THE NIOSOMES

Table 28 LIST OF SOME OF THE POLYMERIC MIXED MICELLES DRUG MANUFACTURER

Table 29 LIST OF NANOSUSPENSION DRUG MANUFACTURER

Table 30 LIST OF SOME OF THE NANOEMULSIONS/MICROEMULSIONS DRUG MANUFACTURER

Table 31 LIST OF SOME OF THE SOLID LIPID NANOPARTICLES DRUG MANUFACTURER

Table 32 GLOBAL NANOPARTICLE COLLOIDAL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT, 2015 – 2024 (USD MILLION)

Table 33 LIST OF SOME OF THE MICROSPHERES DRUG MANUFACTURER

Table 34 GLOBAL MICROPARTICLES COLLOIDAL NOVEL DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

Table 35 LIST OF SOME OF THE FIRST GENERATION LONG ACTING INJECTION

Table 36 LIST OF SOME OF THE SECOND GENERATION LONG ACTING INJECTION:

Table 37 GLOBAL INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)

Table 38 GLOBAL HORMONAL DISORDERS INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)

- Table 39 GLOBAL AUTOIMMUNE DISEASE INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
- Table 40 LIST OF ORPHAN DISEASE IN INDIA (2010)
- Table 41 GLOBAL OTHERS INJECTable DRUG DELIVERY APPLICATION MARKET, BY TYPE, 2015 – 2024 (USD BILLION)
- Table 42 GLOBALINJECTable DRUG DELIVERY USAGE PATTERN MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
- Table 43 GLOBAL INJECTable DRUG DELIVERY MODE OF ADMINISTRATION MARKET, BY TYPE, 2015 – 2024 (USD MILLION)
- Table 44 GLOBAL INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
- Table 45 GLOBAL INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2015 – 2024 (USD MILLION)
- Table 46 GLOBAL INJECTable DRUG DELIVERY MARKET, BY GEOGRAPHY, 2015 – 2024 (USD MILLION)
- Table 47 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)
- Table 48 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
- Table 49 NORTH AMERICA INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
- Table 50 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL,2015 – 2024(USD MILLION)
- Table 51 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
- Table 52 NORTH AMERICA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
- Table 53 NORTH AMERICA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
- Table 54 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT,2015 – 2024(USD MILLION)
- Table 55 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
- Table 56 NORTH AMERICA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
- Table 57 NORTH AMERICA AUTO INJECTORSDEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
- Table 58 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

Table 59 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

Table 60 NORTH AMERICA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

Table 61 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

Table 62 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

Table 63 NORTH AMERICA PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

Table 64 NORTH AMERICA INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)

Table 65 NORTH AMERICA CONVENTIONALDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

Table 66 NORTH AMERICA NOVELDRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

Table 67 NORTH AMERICA COLLOIDALDISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)

Table 68 NORTH AMERICA NANOPARTICLES COLLOIDAL DISPERSIONS DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

Table 69 NORTH AMERICA MICROPARTICLES DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)

Table 70 NORTH AMERICAINJECTable DRUG DELIVERY MARKET, BY APPLICATION,2015 – 2024 (USD MILLION)

Table 71 NORTH AMERICA AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

Table 72 NORTH AMERICA HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

Table 73 NORTH AMERICA OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)

Table 74 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)

Table 75 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)

Table 76 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)

Table 77 NORTH AMERICA INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)

Table 78 U.S. INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD

MILLION)

Table 79 U.S. INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

Table 80 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)

Table 81 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)

Table 82 U.S. CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

Table 83 U.S. SELF INJECTION DEVICE MARKET, BY TYPE,2015 – 2024(USD MILLION)

Table 84 U.S. NEEDLE FREE INJECTORS (NFI)DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

Table 85 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

Table 86 U.S. NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

Table 87 U.S. AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

Table 88 U.S. AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)

Table 89 U.S. AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 – 2024(USD MILLION)

Table 90 U.S. AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

Table 91 U.S. PEN INJECTORS DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)

Table 92 U.S. PEN INJECTORS DEVICE MARKET, BY DESIGN,2015 – 2024(USD MILLION)

Table 93 U.S. PEN INJECTORS DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)

Table 94 U.S. INJECTable DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE, 2015– 2024 (USD MILLION)

Table 95 U.S. CONVENTIONAL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

Table 96 U.S. NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE 2015 – 2024 (USD MILLION)

Table 97 U.S. COLLOIDAL DISPERSION DRUG DELIVERY FORMULATION, BY TYPE 2015 – 2024 (USD MILLION)

- Table 98 U.S. NANOPARTICLES COLLOIDAL DISPERSIONS NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
- Table 99 U.S. MICROPARTICLES NOVEL DRUG DELIVERY FORMULATIONS, BY TYPE, 2015– 2024 (USD MILLION)
- Table 100 U.S. INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
- Table 101 U.S. AUTOIMMUNE DISEASES INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
- Table 102 U.S. HORMONAL DISORDERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
- Table 103 U.S. OTHERS INJECTable DRUG DELIVERY MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION)
- Table 104 U.S. INJECTable DRUG DELIVERY MARKET, BY USAGE PATTERN, 2015– 2024 (USD MILLION)
- Table 105 U.S. INJECTable DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION, 2015– 2024 (USD MILLION)
- Table 106 U.S. INJECTable DRUG DELIVERY MARKET, BY END USER, 2015– 2024 (USD MILLION)
- Table 107 U.S. INJECTable DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 2015– 2024 (USD MILLION)
- Table 108 CANADA INJECTable DRUG DELIVERY MARKET, BY TYPE, 2015 – 2024(USD MILLION)
- Table 109 CANADA INJECTable DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)
- Table 110 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY MATERIAL, 2015 – 2024(USD MILLION)
- Table 111 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY PRODUCT TYPE, 2015 – 2024(USD MILLION)
- Table 112 CANADA CONVENTIONAL INJECTable DRUG DELIVERY DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
- Table 113 CANADA SELF INJECTION DEVICE MARKET, BY TYPE, 2015 – 2024(USD MILLION)
- Table 114 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY PRODUCT, 2015 – 2024(USD MILLION)
- Table 115 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY TECHNOLOGY, 2015 – 2024(USD MILLION)
- Table 116 CANADA NEEDLE FREE INJECTORS (NFI) DEVICE MARKET, BY USABILITY, 2015 – 2024(USD MILLION)
- Table 117 CANADA AUTO INJECTORS DEVICE MARKET, BY PRODUCT, 2015 –

2024(USD MILLION)

Table 118 CANADA AUTO INJECTORS DEVICE MARKET, BY TECHNOLOGY, 2015

– 2024(USD MILLION)

Table 119 CANADA AUTO INJECTORS DEVICE MARKET, BY DESIGN, 2015 –

2024(USD MILLION)

Table 120 CANADA AUTO INJECTORS DEVICE MARKET, BY USABILITY, 2015 –

2024(USD MILLION)



## List Of Figures

### LIST OF FIGURES

:

Figure 1 GLOBAL INJECTable DRUG DELIVERY MARKET: SEGMENTATION

Figure 2 GLOBAL INJECTable DRUG DELIVERY MARKET: GEOGRAPHIC SCOPE

Figure 3 GLOBAL INJECTable DRUG DELIVERY MARKET: DATA TRIANGULATION

Figure 4 GLOBAL INJECTable DRUG DELIVERY MARKET: RESEARCH SNAPSHOT

Figure 5 GLOBAL INJECTable DRUG DELIVERY MARKET: BOTTOM UP APPROACH

Figure 6 GLOBAL INJECTable DRUG DELIVERY MARKET: TOP DOWN APPROACH

Figure 7 GLOBAL INJECTable DRUG DELIVERY MARKET: INTERVIEW

DEMOGRAPHICS

Figure 8 FIGURE: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE INJECTable DRUG DELIVERY MARKET

Figure 9 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR INJECTable DRUG DELIVERY IN 2016 AND APAC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD TO 2024

Figure 10 TECHNOLOGICAL DEVELOPMENT AND INCREASING PREVALENCE OF CHRONIC DISEASES ARE EXPECTED TO DRIVE THE MARKET FOR INJECTable DRUG DELIVERY IN THE FORECAST PERIOD 2017 TO 2024

Figure 11 INJECTable DRUG DELIVERY FORMULATION MARKET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INJECTable DRUG DELIVERY MARKET IN 2017 & 2024

Figure 12 NORTH AMERICA IS THE HIGHEST GROWING AND MOST PROFITable REVENUE POCKETS FOR INJECTable DRUG DELIVERY MANUFACTURERS IN THE FORECAST PERIOD TO 2024

Figure 13 GLOBAL INJECTable DRUG DELIVERY MARKET: BY TYPE, SNAPSHOT 2016

Figure 14 GLOBAL INJECTable DRUG DELIVERY MARKET: BY APPLICATION, SNAPSHOT 2016

Figure 15 GLOBAL INJECTable DRUG DELIVERY MARKET: BY USAGE PATTERN, SNAPSHOT 2016

Figure 16 GLOBAL INJECTable DRUG DELIVERY MARKET: BY MODE OF ADMINISTRATION, SNAPSHOT 2016

Figure 17 GLOBAL INJECTable DRUG DELIVERY MARKET DOMINATED BY HOSPITAL AND CLINICS SEGMENT

Figure 18 GLOBAL INJECTable DRUG DELIVERY MARKET: BY END-USER, SNAPSHOT 2016

Figure 19 GLOBAL INJECTable DRUG DELIVERY MARKET: BY DISTRIBUTION

CHANNEL, SNAPSHOT 2016

Figure 20 NORTH AMERICA INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)

Figure 21 EUROPEAN INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)

Figure 22 ASIA GLOBAL INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)

Figure 23 SOUTH AMERICA INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)

Figure 24 MEA GLOBAL INJECTable DRUG DELIVERY MARKET SNAPSHOT (2017)

Figure 25 GLOBAL INJECTable DRUG DELIVERY MARKET: COMPANY SHARE 2016 (%)

Figure 26 BECTON, DICKINSON AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

Figure 27 BECTON, DICKINSON AND COMPANY: REVENUE ANALYSIS

Figure 28 PFIZER, INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

Figure 29 PFIZER, INC.: REVENUE ANALYSIS

Figure 30 BAXTER INTERNATIONAL INC.: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

Figure 31 BAXTER INTERNATIONAL, INC.: REVENUE ANALYSIS

Figure 32 GERRESHEIMER AG: REVENUE ANALYSIS

Figure 33 SCHOTT AG INC.: REVENUE ANALYSIS

Figure 34 ALKERMES INC.: REVENUE ANALYSIS

Figure 35 ANTARES PHARMA: REVENUE ANALYSIS

Figure 36 BESPAC: REVENUE ANALYSIS

Figure 37 ELCAM MEDICAL: REVENUE ANALYSIS

Figure 38 ELI LILLY AND COMPANY: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

Figure 39 ELI LILLY AND COMPANY: REVENUE ANALYSIS

Figure 40 HASELMEIER: REVENUE ANALYSIS

Figure 41 MYLAN N.V.: REVENUE ANALYSIS

Figure 42 NOVO NORDISK: REVENUE ANALYSIS

Figure 43 OWEN MUMFORD LTD: REVENUE ANALYSIS

Figure 44 SANDOZ INTERNATIONAL GMBH: REVENUE ANALYSIS

Figure 45 SANOFI: REVENUE ANALYSIS

Figure 46 TERUMO CORPORATION: REVENUE ANALYSIS

Figure 47 TEVA PHARMACEUTICAL: SWOT (STRENGTH, WEAKNESS, OPPORTUNITIES AND THREATS)

Figure 48 TEVA PHARMACEUTICAL: REVENUE ANALYSIS

Figure 49 WEST PHARMACEUTICAL SERVICES, INC: REVENUE ANALYSIS

## Figure 50 YPSOMED HOLDING AG: REVENUE ANALYSIS

## I would like to order

Product name: Global IUCD Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

Product link: <https://marketpublishers.com/r/G061308FDE6EN.html>

Price: US\$ 4,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G061308FDE6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

